PAPER Hida M, Yasuda K, Toyokawa M, Asada-Utsugi M, Toda S, Yanagida N, Takahashi R, Kinoshita A, Maki T

Amyloidogenic and non-amyloidogenic pathways of amyloid precursor protein processing in oligodendrocytes.

Brain Res. 2025 May 15;1855:149601. Epub 2025 Mar 26 PubMed.

PAPER Zargaham MK, Ibrahim A, Ahmed M, Babar MM, Rajadas J

Targeting amyloidogenic proteins through cyclic peptides- A medicinal chemistry perspective.

Bioorg Med Chem. 2025 Jun 1;123:118165. Epub 2025 Mar 19 PubMed.

PAPER Gaubert S, Garces P, Hipp J, Bruña R, Lopéz ME, Maestu F, Vaghari D, Henson R, Paquet C, Engemann DA

Exploring the neuromagnetic signatures of cognitive decline from mild cognitive impairment to Alzheimer's disease dementia.

EBioMedicine. 2025 Apr;114:105659. Epub 2025 Mar 27 PubMed.

James Noble on Donanemab Clinical Use Growing in U.S., Rejected in Europe

COMMENT Our center began offering donanemab earlier this year. Patient discussions around decisions of prescribing lecanemab versus donanemab principally reflect the data and findings which were already known, as published in the randomized, controlled, clinical

Donanemab Clinical Use Growing in U.S., Rejected in Europe

RESEARCH NEWS 2025-03-29 Research News Like lecanemab before it, donanemab’s path to market has been slow and rocky. In the U.S., the antibody received Food and Drug Administration approval about nine months ago, but only a few hundred people are on it yet. In Europe, the Committ

PAPER Rabinovici GD, Selkoe DJ, Schindler SE, Aisen P, Apostolova LG, Atri A, Greenberg SM, Hendrix SB, Petersen RC, Weiner M, Salloway S, Cummings J

Donanemab: Appropriate use recommendations

Alzheimer's and Dementia, 2025 . Alzheimers & Dementia

Hamilton Oh

Icahn School of Medicine at Mount Sinai
United States

Plaque Removal Delays Onset of Familial Alzheimer’s Disease

RESEARCH NEWS 2025-03-29 Research News The first evidence that removing amyloid plaques may delay Alzheimer’s symptoms has now been published. In The Lancet Neurology on March 19, scientists led by Randall Bateman at Washington University in St. Louis described findings from the

PAPER Whitehouse C, Bravington E, Patir A, Wei W, Brownlees J, He Y, Corbett N

Investigating Connectivity Deficits in Alzheimer's Disease Using a Novel 3D Bioprinted Model Designed to Quantify Neurite Outgrowth.

Bioengineering (Basel). 2025 Feb 28;12(3) PubMed.

PAPER Lohkamp KJ, Timmer N, Solé Guardia G, Shenk J, Verweij V, Geenen B, Dederen PJ, Bakker L, Egitimci C, Yoldas R, Verhaeg M, Kothuis J, Nieuwenhuis D, Wiesmann M, Kiliaan AJ

Sex-Specific Adaptations in Alzheimer's Disease and Ischemic Stroke: A Longitudinal Study in Male and Female APPswe/PS1dE9 Mice.

Life (Basel). 2025 Feb 21;15(3) PubMed.

PAPER Roberts H, Fang Y, Quinn K, Hill T, Peck MR, Bartke A, Hascup KN, Hascup ER

Lifespan of male and female APP/PS1 and APPNL-F/NL-F mouse models of Alzheimer's disease.

J Alzheimers Dis. 2025 Mar 26;:13872877251325878. Epub 2025 Mar 26 PubMed.

PAPER Liu Q, Ouyang Y, Wang Y, Zhou S, Zhan Y, Wang L

Multianalyte Nanopore Detection of Alzheimer's Biomarkers: A Label-Free Platform with Improved Sensitivity and Range.

Adv Healthc Mater. 2025 Mar 24;:e2405058. Epub 2025 Mar 24 PubMed.

PAPER Qi Z, Guo W, Cui M, Lu J

Synthesis and Evaluation of Novel 18F-labeled Oxadiazole-based Positron Emission Tomography Tracers for β-Amyloid.

Radiat Res. 2025 Mar 24; Epub 2025 Mar 24 PubMed.

PAPER Gui S, Zeng F, Wu Z, Nonaka S, Sano T, Ni J, Nakanishi H, Moriyama M, Kanematsu T

Lipopolysaccharides from Porphyromonas gingivalis indirectly induce neuronal GSK3β-dependent synaptic defects and cause cognitive decline in a low-amyloid-β-concentration environment in Alzheimer's disease.

J Alzheimers Dis. 2025 Mar 20;:13872877251326879. Epub 2025 Mar 20 PubMed.

PAPER Zhu G, Zhang H, Xie R, Younis MR, Fu S, Wang X, Liu B, Li K, Lui S, Wu M

Monitoring Acidification Preceding Aβ Deposition in Alzheimer's Disease.

Adv Healthc Mater. 2025 Mar 19;:e2404907. Epub 2025 Mar 19 PubMed.